$2.45 -$0.07 (-2.8%)

04:00 PM EST on 11/11/19

Inovio Biomedical Corp (NASDAQ:INO)

CAPS Rating: 1 out of 5

A biomedical company which deals in developing human applications of electroporation, which uses brief, controlled electrical pulses to increase cellular uptake of a useful biopharmaceuticals.

Current Price $2.45 Mkt Cap $249.5M
Open $2.48 P/E Ratio 0.00
Prev. Close $2.52 Div. (Yield) $0.00 (0.0%)
Daily Range $2.41 - $2.50 Volume 808,725
52-Wk Range $1.92 - $5.11 Avg. Daily Vol. 630,461

Caps

How do you think NASDAQ:INO will perform against the market?

Add Stock to CAPS Watchlist

All Players

194 Outperform
27 Underperform
 

All-Star Players

15 Outperform
15 Underperform
 

Wall Street

4 Outperform
1 Underperform
 

Top NASDAQ:INO Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

ColossalSlug (< 20)
Submitted March 13, 2014

Inovio has roughly a dozen vaccines in current trial that are very promising as indicated in previous studies. In addition to the keen abilities in R&D by some of the best researchers in the business, their partnerships are solid and will be… More

zzlangerhans (99.80)
Submitted April 05, 2016

I can't really claim that Inovio is a bogus biotech. After all, they've gotten VGX-3100 to the threshold of phase III and achieved reasonably significant deals with Roche and MedImmune. Nevertheless, I think 670M is a generous valuation in a shaky… More

Recent Community Commentary

Read the most recent pitches from players about INO.

Recs

1
Member Avatar zzlangerhans (99.80) Submitted: 4/5/2016 2:20:05 PM : Underperform Start Price: $9.88 NASDAQ:INO Score: +124.47

I can't really claim that Inovio is a bogus biotech. After all, they've gotten VGX-3100 to the threshold of phase III and achieved reasonably significant deals with Roche and MedImmune. Nevertheless, I think 670M is a generous valuation in a shaky market for biotech given the company's long history of operations without any approved products and constantly-changing focus. Most of their current pipeline is in early stage trials and it will be a long time before the VGX-3100 phase III trial generates a significant catalyst. Cash of 183M is respectable but he quarterly burn is in the teens. This might not be an intuitive short but could be used as a counterweight for beloved long positions that are showing stretchmarks amid this spring sector rebound.

Recs

1
Member Avatar allstar31 (99.89) Submitted: 9/12/2014 10:58:34 PM : Underperform Start Price: $10.40 NASDAQ:INO Score: +132.14

Uses known stock promoter Redchip.com, for a pump and dump scheme. Garbage.

Recs

0
Member Avatar Ronbo69 (< 20) Submitted: 7/22/2014 10:13:49 PM : Outperform Start Price: $13.87 NASDAQ:INO Score: -137.68

How about a company with enough money to continue R&D work without any help from the big Pharma, Things are looking good going into results from Ph. II clinical, and with many other ongoing projects, eg. prostate research, things are very exciting.

Leaderboard

Find the members with the highest scoring picks in INO.

Score Leader

InsiderAlerts

InsiderAlerts (< 20) Score: +386.96

The Score Leader is the player with the highest score across all their picks in INO.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
BicaChica 81.46 8/3/2009 Underperform 5Y $9.44 -74.05% +210.20% +284.25 0 Comment
epc53 27.75 7/31/2009 Underperform 5Y $8.48 -71.11% +212.39% +283.49 0 Comment
rhinomaj 92.79 8/4/2009 Underperform 3M $8.36 -70.70% +208.68% +279.38 0 Comment
uconn777 < 20 7/1/2010 Underperform 5Y $4.08 -39.95% +202.90% +242.85 0 Comment
guru111melbourne 80.03 11/24/2009 Underperform 5Y $6.20 -60.48% +177.79% +238.28 0 Comment
bdg10 < 20 1/12/2011 Underperform 5Y $5.84 -58.05% +140.25% +198.29 0 Comment
KidJones 31.73 9/3/2013 Underperform 5Y $7.16 -65.78% +86.62% +152.40 0 Comment
rqtect < 20 2/2/2012 Underperform 3W $3.00 -18.33% +132.31% +150.65 0 Comment
rlm02002 < 20 11/4/2013 Underperform 5Y $7.60 -67.76% +74.51% +142.28 0 Comment
soonerbear98 < 20 5/15/2014 Underperform 5Y $8.48 -71.11% +63.43% +134.54 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for INO.